niacinamide has been researched along with Bleeding in 18 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with the VEGFR tyrosine-kinase inhibitors sunitinib and sorafenib is associated with a significant increase in risk of bleeding." | 8.85 | Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. ( Choueiri, TK; Je, Y; Schutz, FA, 2009) |
| "Sorafenib is the standard of care for advanced hepatocellular carcinoma (HCC)." | 7.81 | Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors. ( Boucher, E; Brunot, A; Cattenoz, C; Crouzet, L; Edeline, J; Gédouin, D; Guillygomarc'h, A; Larible, C; Latournerie, M; Le Roy, F; Le Sourd, S, 2015) |
| "Sorafenib is a multikinase inhibitor recently introduced in the therapy of patients with advanced HCC." | 5.37 | Sorafenib, risk of bleeding and spontaneous rupture of hepatocellular carcinoma. A clinical case. ( Caravetta, A; Guarino, R; Mollo, F; Peluso, L; Rombolà, F; Spinoso, A, 2011) |
| "This analysis of both randomized and nonrandomized studies evaluating an antiangiogenic agent in HCC showed that whereas the use of sorafenib was associated with an increased risk of bleeding in HCC, this was primarily for lower-grade events and similar in magnitude to the risk encountered in RCC." | 4.89 | Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies. ( Duffy, A; Greten, TF; Wilkerson, J, 2013) |
| "Treatment with the VEGFR tyrosine-kinase inhibitors sunitinib and sorafenib is associated with a significant increase in risk of bleeding." | 4.85 | Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. ( Choueiri, TK; Je, Y; Schutz, FA, 2009) |
| "Sorafenib is the standard of care for advanced hepatocellular carcinoma (HCC)." | 3.81 | Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors. ( Boucher, E; Brunot, A; Cattenoz, C; Crouzet, L; Edeline, J; Gédouin, D; Guillygomarc'h, A; Larible, C; Latournerie, M; Le Roy, F; Le Sourd, S, 2015) |
| " He was diagnosed with hepatocellular carcinoma in June 2007 and began treatment with sorafenib 200 mg daily in September 2007." | 3.75 | Elevated International Normalized Ratio associated with concurrent use of sorafenib and warfarin. ( Montalvo, RO; Moretti, LV, 2009) |
| " Common adverse events (AEs) were also studied." | 2.52 | Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis. ( Chen, Y; Hong, S; Luo, S; Tan, M; Wang, S; Zhang, L, 2015) |
| "Although both reached severe aplasia of the bone marrow without blastic infiltration, death occurred with neutropenic sepsis." | 2.52 | Hypertension and Life-Threatening Bleeding in Children with Relapsed Acute Myeloblastic Leukemia Treated with FLT3 Inhibitors. ( Aydınok, Y; Balkan, C; Karadaş, N; Kavaklı, K; Önder Siviş, Z; Yılmaz Karapınar, D, 2015) |
| " With expanded clinical experience with this class of agents has come the increasing recognition of the diverse adverse effects related to disturbance of VEGF-dependent physiological functions and homeostasis in the cardiovascular and renal systems, as well as wound healing and tissue repair." | 2.45 | Adverse effects of anticancer agents that target the VEGF pathway. ( Chen, HX; Cleck, JN, 2009) |
| "Advances in understanding the role of vascular endothelial growth factor (VEGF) in normal physiology are giving insight into the basis of adverse effects attributed to the use of VEGF inhibitors in clinical oncology." | 2.44 | Mechanisms of adverse effects of anti-VEGF therapy for cancer. ( Kamba, T; McDonald, DM, 2007) |
| "Sorafenib is a multikinase inhibitor recently introduced in the therapy of patients with advanced HCC." | 1.37 | Sorafenib, risk of bleeding and spontaneous rupture of hepatocellular carcinoma. A clinical case. ( Caravetta, A; Guarino, R; Mollo, F; Peluso, L; Rombolà, F; Spinoso, A, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (22.22) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (33.33) | 29.6817 |
| 2010's | 8 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hong, S | 1 |
| Tan, M | 1 |
| Wang, S | 1 |
| Luo, S | 1 |
| Chen, Y | 1 |
| Zhang, L | 1 |
| Edeline, J | 1 |
| Crouzet, L | 1 |
| Le Sourd, S | 1 |
| Larible, C | 1 |
| Brunot, A | 1 |
| Le Roy, F | 1 |
| Cattenoz, C | 1 |
| Latournerie, M | 1 |
| Gédouin, D | 1 |
| Guillygomarc'h, A | 1 |
| Boucher, E | 1 |
| Yılmaz Karapınar, D | 1 |
| Karadaş, N | 1 |
| Önder Siviş, Z | 1 |
| Balkan, C | 1 |
| Kavaklı, K | 1 |
| Aydınok, Y | 1 |
| Snider, KL | 1 |
| Maitland, ML | 1 |
| Chen, HX | 1 |
| Cleck, JN | 1 |
| Je, Y | 1 |
| Schutz, FA | 1 |
| Choueiri, TK | 1 |
| Moretti, LV | 1 |
| Montalvo, RO | 1 |
| Minor, DR | 1 |
| Rübsam, K | 1 |
| Flaig, MJ | 1 |
| Ruzicka, T | 1 |
| Prinz, JC | 1 |
| Rombolà, F | 1 |
| Caravetta, A | 1 |
| Mollo, F | 1 |
| Spinoso, A | 1 |
| Peluso, L | 1 |
| Guarino, R | 1 |
| Fabries, P | 1 |
| Pauleau, G | 1 |
| Brardjanian, S | 1 |
| Artéaga, C | 1 |
| Guisset, M | 1 |
| Coton, T | 1 |
| Duffy, A | 1 |
| Wilkerson, J | 1 |
| Greten, TF | 1 |
| Robert, C | 1 |
| Faivre, S | 1 |
| Raymond, E | 1 |
| Armand, JP | 1 |
| Escudier, B | 1 |
| Kamba, T | 1 |
| McDonald, DM | 1 |
| Podorozhnyĭ, AP | 1 |
| Fujinaga, Y | 1 |
| Grote, W | 1 |
| Schneider, H | 1 |
| Cervos-Navarro, J | 1 |
7 reviews available for niacinamide and Bleeding
| Article | Year |
|---|---|
Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2015 |
Hypertension and Life-Threatening Bleeding in Children with Relapsed Acute Myeloblastic Leukemia Treated with FLT3 Inhibitors.
Topics: Acidosis; Acute Kidney Injury; Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineo | 2009 |
Adverse effects of anticancer agents that target the VEGF pathway.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2009 |
Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Hemorrhage; Humans; Incidence; I | 2009 |
Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Hemorrhage; Humans; Incid | 2013 |
Mechanisms of adverse effects of anti-VEGF therapy for cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2007 |
11 other studies available for niacinamide and Bleeding
| Article | Year |
|---|---|
Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents; Asthenia; Carcinoma, Hepatocellular; Comorbid | 2015 |
Elevated International Normalized Ratio associated with concurrent use of sorafenib and warfarin.
Topics: Aged; Anticoagulants; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Interactions; Hemorrhage; H | 2009 |
Risk of bleeding not increased by sorafenib or sunitinib.
Topics: Antineoplastic Agents; Benzenesulfonates; Hemorrhage; Humans; Indoles; Neoplasms; Niacinamide; Pheny | 2010 |
Erythema marginatum hemorrhagicum: a unique cutaneous side effect of sorafenib.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Erythema; Hemorrhage; Humans; Liver Neoplasms; M | 2011 |
Sorafenib, risk of bleeding and spontaneous rupture of hepatocellular carcinoma. A clinical case.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Hemorrhage; Humans; Liver | 2011 |
[Metastatic adrenal necrosis under sorafenib treatment for hepatocellular carcinoma].
Topics: Adrenal Gland Diseases; Adrenal Gland Neoplasms; Adrenal Glands; Antineoplastic Agents; Carcinoma, H | 2013 |
Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors?
Topics: Antineoplastic Agents; Benzenesulfonates; Hemorrhage; Humans; Indoles; Nail Diseases; Niacinamide; P | 2005 |
[Vitamin B1, B2, PP, B6 and C metabolism in iron-deficiency anemia].
Topics: Adolescent; Adult; Anemia, Hypochromic; Ascorbic Acid; Female; Free Radicals; Hemorrhage; Humans; Ma | 1982 |
[Effect of Inacin capsule for eye disease].
Topics: Adult; Aged; Capsules; Eye Diseases; Female; Hemorrhage; Humans; Iodides; Male; Middle Aged; Niacina | 1968 |
[Experiments on the induction and prevention of malformations in rabbits].
Topics: Abnormalities, Drug-Induced; Amines; Animals; Animals, Newborn; Antimetabolites; Cell Division; Cong | 1972 |
Acute gliopathy in spinal cord and brain stem induced by 6-aminonicotinamide.
Topics: Animals; Brain Stem; Cats; Cell Nucleus; Cerebellum; Cranial Nerves; Cytoplasm; Endoplasmic Reticulu | 1974 |